Laureate Education (NASDAQ:LAUR) Delivers Impressive Q1
Higher education company Laureate Education (NASDAQ:LAUR) reported revenue ahead of Wall Street's expectations in Q1 CY2025, but sales fell by 14.2% year on year to $236.2 million. The company expects the full year's revenue to be around $1.57 billion, close to analysts' estimates. Its GAAP loss of $0.13 per share was 31.6% above analysts' consensus estimates.
Is now the time to buy Laureate Education? Find out in our full research report.
Revenue: $236.2 million vs analyst estimates of $225.2 million (14.2% year-on-year decline, 4.9% beat)
EPS (GAAP): -$0.13 vs analyst estimates of -$0.19 (31.6% beat)
Adjusted EBITDA: $5.4 million vs analyst estimates of -$5 million (2.3% margin, significant beat)
The company slightly lifted its revenue guidance for the full year to $1.57 billion at the midpoint from $1.56 billion
EBITDA guidance for the full year is $476.5 million at the midpoint, in line with analyst expectations
Operating Margin: -5.6%, down from 4% in the same quarter last year
Free Cash Flow Margin: 22.5%, up from 6.3% in the same quarter last year
Enrolled Students: 477,000, up 17,600 year on year
Market Capitalization: $2.99 billion
Eilif Serck-Hanssen, President and Chief Executive Officer, said, 'We are pleased to report favorable new enrollment results during the recently completed main intake cycle in Peru and secondary intake cycle in Mexico, further reinforcing the resiliency of our business model. With increased visibility into the remainder of the year, we are tightening the range on our full-year 2025 guidance, raising the mid-point for both Revenue and Adjusted EBITDA. We remain confident in the growing demand for quality higher education in both Mexico and Peru even in a time of economic uncertainty, driven by rising participation rates and the significant wage premium earned by graduates. With our leading brands and strong digital capabilities, we are ideally positioned to capitalize on those growth opportunities. In addition, we remain committed to continuing to return excess capital to shareholders, supported by a strong balance sheet and our cash-accretive business model.'
Founded in 1998 by Douglas L. Becker and based in Miami, Laureate Education (NASDAQ:LAUR) is a global network of higher education institutions.
A company's long-term performance is an indicator of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Laureate Education's demand was weak and its revenue declined by 3.4% per year. This was below our standards and suggests it's a lower quality business.
We at StockStory place the most emphasis on long-term growth, but within consumer discretionary, a stretched historical view may miss a company riding a successful new product or trend. Laureate Education's annualized revenue growth of 9.1% over the last two years is above its five-year trend, but we were still disappointed by the results.
Laureate Education also discloses its number of enrolled students, which reached 477,000 in the latest quarter. Over the last two years, Laureate Education's enrolled students averaged 5.7% year-on-year growth. Because this number is lower than its revenue growth during the same period, we can see the company's monetization has risen.
This quarter, Laureate Education's revenue fell by 14.2% year on year to $236.2 million but beat Wall Street's estimates by 4.9%.
Looking ahead, sell-side analysts expect revenue to grow 3.1% over the next 12 months, a deceleration versus the last two years. This projection doesn't excite us and suggests its products and services will see some demand headwinds.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Laureate Education's operating margin might fluctuated slightly over the last 12 months but has generally stayed the same, averaging 22.5% over the last two years. This profitability was elite for a consumer discretionary business thanks to its efficient cost structure and economies of scale.
This quarter, Laureate Education generated an operating profit margin of negative 5.6%, down 9.6 percentage points year on year. This contraction shows it was less efficient because its expenses increased relative to its revenue.
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable.
Sadly for Laureate Education, its EPS declined by 13.5% annually over the last five years, more than its revenue. We can see the difference stemmed from higher interest expenses or taxes as the company actually grew its operating margin and repurchased its shares during this time.
In Q1, Laureate Education reported EPS at negative $0.13, down from negative $0.07 in the same quarter last year. Despite falling year on year, this print easily cleared analysts' estimates. Over the next 12 months, Wall Street expects Laureate Education's full-year EPS of $1.88 to shrink by 20.2%.
We were impressed by how significantly Laureate Education blew past analysts' revenue, EPS, and EBITDA expectations this quarter. We were also glad it raised its full-year revenue guidance. On the other hand, its number of enrolled students missed, but we still think this was a solid quarter with some key areas of upside. The stock traded up 2.3% to $20.50 immediately after reporting.
Laureate Education may have had a good quarter, but does that mean you should invest right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
40 minutes ago
- Yahoo
Insurance tech firm Slide targets over $2 billion valuation in Nasdaq IPO
-- Insurance technology company Slide is pursuing a valuation of up to $2.12 billion in its upcoming initial public offering (IPO) on the Nasdaq exchange. The company disclosed the target in a filing on Monday. In collaboration with some of its existing stakeholders, Slide is aiming to raise up to $340 million from the IPO. This move is in line with a recent trend of successful stock market debuts by insurance firms. Barclays and Morgan Stanley have been named as the lead underwriters for the listing. The shares of the company are anticipated to begin trading on the Nasdaq exchange under the ticker symbol "SLDE". Related articles Insurance tech firm Slide targets over $2 billion valuation in Nasdaq IPO Morgan Stanley downgrades Lululemon on weak US growth outlook Tesla shares slip after double downgrade amid Trump feud fallout Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
40 minutes ago
- Yahoo
Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr
-- Texas Capital has downgraded Sitio Royalties Corp (NYSE:STR) to Hold from Buy after the company agreed to be acquired by Viper Energy (NASDAQ:VNOM) in an all-stock transaction valued at $19.41 per share. The downgrade comes as analysts no longer see material upside following the announced deal, which values Sitio at about $4.1 billion. Texas Capital also cut its price target on Sitio to $20 from $29, in line with the proposed merger terms. 'We are positive on the transaction,' analysts wrote, citing strategic fit, increased scale, low leverage, and an attractive base dividend breakeven below $20 per barrel WTI. 'The combination creates a must-own Minerals company.' Texas Capital does not expect any competing bids given the lack of well-capitalized public rivals in the space. Viper Energy said the deal will make it the largest public mineral and royalty company in the U.S., with positions in the Permian and other key basins. The transaction is expected to close in the second half of 2025, subject to shareholder and regulatory approvals. Related articles Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr Tesla shares gain as Trump wishes Musk 'well' GFL weighs sale in infrastructure arm valued at C$5 billion - Bloomberg Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. 'On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company' commented John Seaberg, Chairman of Anteris. 'On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.' Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR® THV for patients with aortic stenosis. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. For more information: Investor Relations investor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269WebsiteXFacebookLinkedIn in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data